Saturn V Capital Management LP holds a focused book of 21 stocks worth $552.2M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Candel Therapeutics Inc and trimmed Amylyx Pharmaceuticals Inc. Their largest long position is Alumis Inc at 13% of the equity book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Saturn V Capital Management LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Morgan Stanley | 24 / 21 | $844.8M |
| UBS Group AG | 24 / 21 | $825.0M |
| Geode Capital Management, LLC | 23 / 21 | $1.3B |
| Goldman Sachs Group Inc | 23 / 21 | $619.2M |
| Millennium Management LLC | 23 / 21 | $537.1M |
| Bank Of America Corp | 22 / 21 | $615.1M |
| JPMorgan Chase & Co | 22 / 21 | $559.0M |
| BNP Paribas Financial Markets | 22 / 21 | $66.8M |
Ranked by the share of each fund's own book sitting in the names it shares with Saturn V Capital Management LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Alumis Inc COM | $70.5M | 3.20M | 12.8% | ▲+2.1% Added · +66K sh | |
| 2 | Amylyx Pharmaceuticals Inc COM | $60.5M | 4.35M | 10.9% | ▼−3.3% Reduced · −147K sh | |
| 3 | Abivax Sa SPONSORED ADS | $60.4M | 542.7K | 10.9% | ▼−16% Reduced · −106K sh | |
| 4 | Vaxcyte Inc COM | $47.9M | 824.5K | 8.7% | ▲+3.2% Added · +26K sh | |
| 5 | Pharvaris N V COM | $33.9M | 1.20M | 6.1% | ▲+5.4% Added · +61K sh | |
| 6 | Immix Biopharma Inc COM | $33.6M | 3.69M | 6.1% | ▲+23% Added · +694K sh | |
| 7 | Celcuity Inc COM | $32.2M | 281.9K | 5.8% | ▼−11% Reduced · −35K sh | |
| 8 | Jazz Pharmaceuticals PLC SHS USD | $30.8M | 163.0K | 5.6% | ▼−34% Reduced · −85K sh | |
| 9 | Disc Medicine Inc COM | $28.8M | 449.9K | 5.2% | ▲+51% Added · +151K sh | |
| 10 | X4 Pharmaceuticals Inc COM NEW | $26.7M | 6.46M | 4.8% | ▲+11% Added · +656K sh | |
| 11 | Cogent Biosciences Inc COM | $24.1M | 626.6K | 4.4% | ▼−49% Reduced · −590K sh | |
| 12 | Monopar Therapeutics Inc COM NEW | $18.9M | 345.6K | 3.4% | ▲+6.1% Added · +20K sh | |
| 13 | Dyne Therapeutics Inc COM | $17.5M | 966.6K | 3.2% | ▼−46% Reduced · −822K sh | |
| 14 | Invivyd Inc COM | $14.2M | 10.95M | 2.6% | ▲+42% Added · +3.2M sh | |
| 15 | Candel Therapeutics Inc COM | $14.2M | 2.90M | 2.6% | ▲New New position | |
| 16 | Oculis Holding AG ORDINARY SHARES | $13.7M | 516.8K | 2.5% | —Held | |
| 17 | Ovid Therapeutics Inc COM | $9.2M | 4.17M | 1.7% | ▲+67% Added · +1.7M sh | |
| 18 | Inhibikase Therapeutics Inc COM NEW | $6.5M | 3.86M | 1.2% | ▲+0.2% Added · +7K sh | |
| 19 | Zura Bio Ltd CLASS A ORD SHS | $4.4M | 740.0K | 0.8% | ▲New New position | |
| 20 | Alto Neuroscience Inc COM SHS | $2.0M | 89.0K | 0.4% | ▲New New position | |
| 21 | Satellos Bioscience Inc COM | $2.0M | 350.0K | 0.4% | ▲New New position |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1964437/holdings"
Use Arkolith to show Saturn V Capital Management LP's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.